Codex DNA GAAP EPS of -$0.28 Beats by $0.13, Revenue of $9.47M Beats by $2.27M
Seeking AlphaMar 21, 2023 17:00 ET
Telesis Bio (NASDAQ:DNAY) Trading 11.4% Higher
Telesis Bio, Inc. (NASDAQ:DNAY – Get Rating) shares traded up 11.4% on Monday . The company traded as high as $1.95 and last traded at $1.85. 49,762 shares changed hands during mid-day trading, a decl
Financial News LiveMar 8, 2023 19:23 ET
Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer le
GlobeNewswireJan 9, 2023 09:05 ET
Codex DNA Sees 4Q Rev $9M >DNAY
Codex DNA Sees 4Q Rev $9M >DNAY
Dow JonesJan 9, 2023 09:03 ET
Reviewing Telesis Bio (NASDAQ:DNAY) and Arrayit (OTCMKTS:ARYC)
Arrayit (OTCMKTS:ARYC – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of
Defense WorldJan 7, 2023 01:42 ET
News On Codex DNA Inc. (DNAY) Now Under TBIO
News On Codex DNA Inc. (DNAY) Now Under TBIO
Dow JonesJan 4, 2023 17:09 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersQuotient (NASDAQ:QTNT) stock moved upwards by 114.0% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 million. Baudax Bio (NASDAQ:BXRX) sha
Benzinga Real-time NewsDec 29, 2022 08:08 ET
Reviewing Bionano Genomics (NASDAQ:BNGO) & Telesis Bio (NASDAQ:DNAY)
Bionano Genomics (NASDAQ:BNGO – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on
Defense WorldDec 27, 2022 01:11 ET
Critical Comparison: Bionano Genomics (NASDAQ:BNGO) Versus Telesis Bio (NASDAQ:DNAY)
Bionano Genomics (NASDAQ:BNGO – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based o
Financial News LiveDec 24, 2022 23:21 ET
Stocks That Hit 52-Week Lows On Wednesday
 Wednesday saw 219 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Salesforce (NYSE:CRM).Versus Syste
Benzinga Real-time NewsDec 7, 2022 11:42 ET
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 167 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Salesforce (NYSE:CRM) was the largest, in terms of market cap, to set a new 52-week low.The co
Benzinga Real-time NewsDec 6, 2022 12:24 ET
Telesis Bio, Inc. (NASDAQ:DNAY) Short Interest Up 12.3% in October
Telesis Bio, Inc. (NASDAQ:DNAY) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 265,400 shares, an increase of 12.3% from the October 15th total of 236,300 shares.
kopsourceNov 16, 2022 23:31 ET
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates
Yahoo FinanceNov 9, 2022 19:35 ET
KeyBanc Capital Markets Adjusts Price Target on Codex DNA to $5 From $8, Maintains Overweight Rating
09:41 AM EST, 11/09/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
MT NewswiresNov 9, 2022 09:43 ET
Express News | Codex DNA Is Maintained at Overweight by Keybanc
Moomoo 24/7Nov 9, 2022 04:59 ET
Codex DNA Price Target Cut to $5.00/Share From $8.00 by Keybanc
Codex DNA Price Target Cut to $5.00/Share From $8.00 by Keybanc
Dow JonesNov 9, 2022 04:59 ET
Codex DNA Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/09/2022 199.4% Keybanc $8 → $5 Maintains Overweight 03/28/2022 379.04% Keybanc $30 → $8 Maintains Overw
Benzinga Analyst RatingsNov 9, 2022 04:51 ET
Keybanc Maintains Overweight on Codex DNA, Lowers Price Target to $5
Keybanc analyst Paul Knight maintains Codex DNA (NASDAQ:DNAY) with a Overweight and lowers the price target from $8 to $5.
Benzinga Real-time NewsNov 9, 2022 04:51 ET
Telesis Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Results and Raised FY22 Guidance.
Telesis Bio shares are trading higher after the company reported better-than-expected Q3 results and raised FY22 guidance.
BenzingaNov 8, 2022 17:36 ET
Telesis Bio Q3 EPS $(0.42) Beats $(0.48) Estimate, Sales $6.68M Beat $5.30M Estimate
Telesis Bio (NASDAQ:DNAY) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 23.53 percent decrease over losses of $(0.34) p
Benzinga Real-time NewsNov 8, 2022 16:43 ET
No Data
No Data